Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Drop in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 34,500 shares, a decline of 31.7% from the September 30th total of 50,500 shares. Currently, 2.5% of the shares of the company are sold short. Based on an average daily trading volume, of 106,300 shares, the days-to-cover ratio is currently 0.3 days.

Insider Transactions at Vaccinex

In related news, Director Albert Friedberg bought 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were acquired at an average price of $6.15 per share, with a total value of $1,230,000.00. Following the completion of the transaction, the director now owns 762,415 shares of the company’s stock, valued at $4,688,852.25. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders bought 203,753 shares of company stock worth $1,247,255. 51.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Vaccinex

An institutional investor recently raised its position in Vaccinex stock. AIGH Capital Management LLC raised its holdings in Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,958 shares of the company’s stock after buying an additional 50,593 shares during the quarter. AIGH Capital Management LLC owned 6.90% of Vaccinex worth $707,000 as of its most recent SEC filing. Institutional investors and hedge funds own 50.11% of the company’s stock.

Vaccinex Price Performance

VCNX stock traded up $0.36 on Monday, reaching $3.74. 171,852 shares of the company were exchanged, compared to its average volume of 49,938. Vaccinex has a 12 month low of $1.39 and a 12 month high of $13.45. The stock’s fifty day moving average price is $4.11 and its 200 day moving average price is $5.35. The firm has a market capitalization of $6.47 million, a PE ratio of -0.06 and a beta of 0.96.

Vaccinex (NASDAQ:VCNX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($3.10) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.